Residual Effects of Middle-of-the-Night Administration of Zaleplon and Zolpidem on Driving Ability, Memory Functions, and Psychomotor Performance

Thirty healthy volunteers participated in this two-part study. Part 1 was a single-blind, two-period crossover design to determine the effects of a single dose of ethanol (0.03% < BAC < 0.05%) or ethanol-placebo on driving ability, memory, and psychomotor performance. Part 2 was a double-blind, five-period crossover design to measure the effects of a middle-of-the-night administration of zaleplon 10 or 20 mg, zolpidem 10 or 20 mg, or placebo on driving ability 4 hours after administration and memory and psychomotor performance 6 hours after administration. The on-the-road driving test consisted of operating an instrumented automobile over a 100-km highway circuit at a constant speed (95 km/h) while maintaining a steady lateral position between the right lane boundaries. The standard deviation of lateral position (SDLP) was the primary performance parameter of the driving test. The psychomotor and memory test battery consisted of the Word Learning Test, the Critical Tracking Test, the Divided Attention Test, and the Digit Symbol Substitution Test. Data for each part were analyzed separately using ANOVA for crossover designs. Zaleplon 10 and 20 mg did not significantly impair driving ability 4 hours after middle-of-the-night administration. Relative to placebo, after zolpidem 10 mg, SDLP was significantly elevated, but the magnitude of the difference was small and not likely to be of clinical importance. Memory and psychomotor test performance was unaffected after both doses of zaleplon and zolpidem 10 mg. In contrast, zolpidem 20 mg significantly increased SDLP and speed variability. Further, zolpidem 20 mg significantly impaired performance on all psychomotor and memory tests. Finally, driving performance, Digit Symbol Substitution Test, Divided Attention Test, and immediate and delayed free recall of the Word Learning Test were significantly impaired after ethanol. The results show that zaleplon (10 and 20 mg) is a safe hypnotic devoid of next-morning residual impairment when used in the middle of the night.

[1]  A. Declerck,et al.  Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo , 1995 .

[2]  I. Lucki,et al.  Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. , 2000, Journal of clinical psychopharmacology.

[3]  E. Volkerts,et al.  Specific review of the psychometric effects of cetirizine , 1995, Allergy.

[4]  P. Simon,et al.  Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo. , 1990, British journal of clinical pharmacology.

[5]  F. Couper,et al.  Zolpidem and driving impairment. , 2001, Journal of forensic sciences.

[6]  T J Balkin,et al.  Effects of daytime administration of zolpidem and triazolam on performance. , 1996, Aviation, space, and environmental medicine.

[7]  J. Boudet,et al.  Effects of zolpidem on sleep architecture, night time ventilation, daytime vigilance and performance in heavy snorers. , 1994, British journal of clinical pharmacology.

[8]  R. Griffiths,et al.  Triazolam and zolpidem: effects on human memory and attentional processes , 1999, Psychopharmacology.

[9]  R. Griffiths,et al.  Selective effects of zolpidem on human memory functions , 1999, Journal of psychopharmacology.

[10]  T. Hergueta,et al.  Comparison of the Effects of Zolpidem and Triazolam on Memory Functions, Psychomotor Performances, and Postural Sway in Healthy Subjects , 1993, Journal of clinical psychopharmacology.

[11]  E R Volkerts,et al.  Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. , 1995, Journal of clinical psychopharmacology.

[12]  Neil Stanley,et al.  Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening , 2001, Human psychopharmacology.

[13]  J. Jolles,et al.  Mechanisms of drug‐induced driving impairment: a dimensional approach , 1998 .

[14]  E. Volkerts,et al.  A comparative study of on‐the‐road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg , 1992 .

[15]  Edmund R. Volkerts,et al.  Driving and Benzodiazepine Use , 1998 .

[16]  W. Cevallos,et al.  A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. , 2001, British journal of clinical pharmacology.

[17]  K. Goa,et al.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. , 2000, Drugs.

[18]  H. Kalska,et al.  Effects of Alcohol, Zolpidem, and Some Other Sedatives and Hypnotics on Human Performance and Memory , 1998, Pharmacology Biochemistry and Behavior.

[19]  T. Balkin,et al.  Effects of daytime administration of zolpidem versus triazolam on memory , 2004, European Journal of Clinical Pharmacology.

[20]  A. Vermeeren,et al.  Residual effects of evening and middle‐of‐the‐night administration of zaleplon 10 and 20 mg on memory and actual driving performance , 1998 .

[21]  D. Jones,et al.  Effects of zolpidem on saccadic eye movements and psychomotor performance: a double-blind, placebo controlled study in healthy volunteers. , 1993, British journal of clinical pharmacology.

[22]  G. Plosker,et al.  Zaleplon: a review of its use in the treatment of insomnia. , 2000, Drugs.

[23]  Kerstin Dmgen,et al.  Zaleplon displays a selectivity to recombinant GABAA receptors different from zolipdem, zopiclone and benzodiazepines , 1999 .

[24]  J F O'Hanlon,et al.  Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies. , 1995, Neuropsychobiology.

[25]  D. Stanski,et al.  Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. , 2000, Clinical therapeutics.

[26]  D. Armstrong,et al.  Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects. , 1998, Journal of clinical psychopharmacology.

[27]  D. Greenblatt,et al.  Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo , 1998, Clinical pharmacology and therapeutics.

[28]  O. Etard,et al.  Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades , 1999, Psychopharmacology.